Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 5, 2004

View Archived Issues

Oral tacrolimus shows promise in steroid-refractory ulcerative colitis

Boehringer Ingelheim scientists claim new antiproliferative agents

New nAChR ligands and their use described by Aventis and Targacept

Novel beta3-adrenoceptor agonists covered by Kissei patent

Non-hemolytic indolicidin-based antibiotics identified by Indian researchers

Optically active calcium antagonists and their use in hypertension and other disorders

New antiangiogenic kinase inhibitors discovered at Cellular Genomics

French team identifies new G-quadruplex-binding telomerase inhibitors

Santaris describes novel potent Bcl-2 inhibitor SPC-2004

ANG-704: A metabolically stable bioreductive prodrug of combretastatin A4

Multiple targets elucidated for anti-GI cancer agent HKH-40A

AP-23573 enters phase II study for bone and soft tissue sarcomas

Pierre Fabre to commercialize Olux in Europe

Enbrel approved in E.U. for psoriasis

Gilead Sciences and Genelabs collaborate in HCV

U.K. approval for QVAR in Easi-Breathe inhaler

GenPat77 and MedImmune sign agreement on novel therapeutic target

Approvable letter for SnET2 for AMD

Tarceva NDA accepted for priority review

Primovist completes European mutual recognition procedure

FDA approves Remicade as first-line therapy in moderate to severe RA

Kissei takes option to Japanese license for YSCMA

RTA-203: a new mammalian V-ATPase inhibitor in preclinical testing

Good pharmacokinetic profiles reported for single-dose and twice-daily LBM-415

A PABA combination regimen shows promise in refractory melanoma

New data on the bactericidal activity of RO-4908463

Abilify approved for acute bipolar mania

Doripenem shows good antibacterial activity against a large number of clinical isolates

Single oral doses of palosuran are reported safe in healthy volunteers

DA-9601 increases ghrelin, leptin in peptic ulcer models

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 5, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Study identifies CAND1 as therapeutic target in hepatoblastoma
BioWorld Science
Hepatoblastoma is the most common liver cancer during childhood, with limited therapeutic options in aggressive or relapsed cases. NEDDylation is a...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...